Why Synchronoss Technologies Shares Plunged
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Synchronoss Technologies have plunged today by as much as 12% after Goldman Sachs downgraded the company.
So what: Goldman dropped its rating on Synchronoss from "neutral" to "sell," while reducing its price target from $28 to $27. Analyst Paul Thomas is skeptical of user adoption of cloud services, which Synchronoss is relying on.
Now what: Thomas makes a comparison to Apple, saying that Synchronoss would need to see adoption rates accelerate to match iCloud's launch in order to reach consensus estimates. Just to hit the midpoint of fiscal 2013 sales guidance, Synchronoss would need 19 million subscribers in the second half, by Goldman's estimates. The analyst is cautious of the company's ability to do so, and his estimates are below the rest of the Street.
Interested in more info on Synchronoss Technologies? Add it to your watchlist by clicking here.
It's incredible to think just how much of our digital and technological lives are almost entirely shaped and molded by just a handful of companies. Find out "Who Will Win the War Between the 5 Biggest Tech Stocks?" in The Motley Fool's latest free report, which details the knock-down, drag-out battle being waged by the five kings of tech. Click here to keep reading.
The article Why Synchronoss Technologies Shares Plunged originally appeared on Fool.com.
Fool contributor Evan Niu, CFA, owns shares of Apple. The Motley Fool recommends Apple and Goldman Sachs. The Motley Fool owns shares of Apple. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
